文献速递甲状腺疾病

剂量等效左甲状腺素品牌强制转换对血浆促甲状腺素的影响:一项队列研究

Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study.
PubMed 文献 · Thyroid · 2020-05-04

在荷兰开展观察性队列研究,纳入使用左甲状腺素(LT4)品牌Thyrax®至少25 μg/日且持续一年以上的患者,比较因短缺而剂量等效换用其他品牌者与继续使用Thyrax者的血浆促甲状腺素(TSH)。继续使用Thyrax的甲状腺功能正常患者中19%–24%在至少6周后TSH超出参考范围,而剂量等效换药后该比例升至24%–63%,提示换药可能导致大量患者需要调整剂量。

要点

  • 使用≤100 μg Thyrax的甲状腺功能正常患者,继续用药者TSH超出参考范围为19%,换药者为24%(p < 0.0001)。
  • 使用>100 μg Thyrax的患者,继续用药者TSH超出参考范围为24%,换药者为63%(p < 0.0001)。
  • 使用>50 μg Thyrax的患者剂量等效换药后发生甲状腺功能亢进的可能性是继续使用Thyrax者的四至五倍。

核心结论

  • 继续使用相同剂量Thyrax的甲状腺功能正常患者中,至少6周后19%–24%的患者TSH超出参考范围。
  • 从Thyrax剂量等效换用其他LT4品牌后,更大比例(24%–63%)的患者出现生化意义上的药物过量征象。
  • 结果表明剂量等效的LT4品牌转换可能使大量患者需要调整剂量。

研究设计与样本

  • 观察性队列研究,使用代表荷兰人群的两个登记数据库:Nivel初级保健数据库和PHARMO数据库网络。
  • 纳入每日使用至少25 μg Thyrax且持续一年或更长的患者。
  • 形成两个队列:换药队列为2016年从Thyrax换用其他品牌且在换药前后同一LT4剂量下各有一次连续TSH测定的患者;Thyrax队列为继续使用Thyrax且间隔6周有两次连续TSH测定的患者。

主要发现

  • 在Thyrax队列中,使用≤100 μg的甲状腺功能正常患者有19%在后续测定时TSH超出参考范围,换药队列为24%(p < 0.0001)。
  • 使用>100 μg Thyrax的患者中,上述比例分别为24%和63%(p < 0.0001)。
  • 使用>50 μg Thyrax的患者剂量等效换用其他品牌后发生甲状腺功能亢进的可能性是继续使用Thyrax者的四至五倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Patients with primary hypothyroidism are treated with levothyroxine (LT4) to normalize their serum thyrotropin (TSH). Finding the optimal dosage is a long-lasting process, and a small change can have major impact. Currently, limited data are available on the impact of dose-equivalent substitution between brands. This study aimed to determine the effect of the shortage of the LT4 brand Thyrax® in the Netherlands and the resulting dose-equivalent switch to another brand on plasma TSH concentrations in a large cohort of patients. Methods: Observational cohort study. Two registries representative for the Dutch population containing prescription and laboratory test data: the Nivel Primary Care Database and the PHARMO Database Network. Patients using at least 25 μg Thyrax daily for one year or longer were included. Two cohorts were formed: a switch cohort consisting of patients who switched from Thyrax to an alternative brand, and a Thyrax cohort including patients who continued to use Thyrax. Patients in the switch cohort did switch from Thyrax to a different brand of LT4 in 2016 and had two consecutive TSH measurements on the same dose of LT4, one before and one 6 weeks after the switch. Patients in the Thyrax cohort had two consecutive TSH measurements on the same dose of Thyrax that were 6 weeks apart. Results: In the Thyrax cohort, 19% of euthyroid patients using ≤100 μg had a TSH level outside the reference range at the subsequent measurement compared with 24% in the switch cohort (p < 0.0001). For patients using >100 μg Thyrax, these figures were 24% and 63%, respectively (p < 0.0001). Furthermore, patients using >50 μg Thyrax were four to five times more likely to become hyperthyroid after a dose-equivalent switch to a different brand compared with patients who stayed on Thyrax. Conclusions: In euthyroid patients continuing the LT4 product Thyrax at the same dose, TSH was out of range in 19-24% at least 6 weeks later. A dose-equivalent switch from Thyrax to other LT4 brands induced biochemical signs of overdosing in an even larger proportion (24-63%) of patients. The results indicate that a dose-equivalent LT4 brand switch may necessitate a dose adjustment in a large number of patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Flinterman LE, Kuiper JG, Korevaar JC, et al. Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study. Thyroid. 2020. PMID: 32188356. doi:10.1089/thy.2019.0414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。